Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
eDiary collected patient results for approved drug
Pittsburgh-When the FDA recently approved ketorolac tromethamine ophthalmic solution (Acular LS 0.4%, Allergan), history was made on several fronts. Not only was it a banner day for Allergan, whose solution won approval, but it represented the first time an electronic patient diary was used to collect and tabulate primary efficacy data for a phase III pivotal trial.
Related Videos
Related Content
